Qyuns Therapeutics Co., Ltd. (QYUNS-B) Aktie

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn's disease. The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.